Positron Emission Tomography
Articles tagged with Positron Emission Tomography
Head and neck tumors: Modern imaging provides clues to aggressive progression
A study by Medical University of Vienna shows that PET/CT scans can detect aggressive forms of head and neck cancer at an early stage due to specific patterns reflecting biological activity. Modern imaging helps identify targeted treatment strategies for a type of cancer difficult to treat.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: May 4, 2026
Recent research published in The Journal of Nuclear Medicine has made significant advancements in brain imaging and cancer treatment. A new wearable brain imaging system, SmartBrain, enables real-time imaging beyond the lab, capturing high-resolution images of brain activity without requiring patients to remain still.
Novel theranostic approach for radioimmunotherapy achieves curative responses in colorectal cancer tumors
A new pretargeted radioimmunotherapy technique has been shown to be effective and safe in eradicating tumors from a preclinical colorectal cancer model. The multi-step theranostic approach delivers alpha-emitting radiation directly to tumors while limiting exposure to healthy tissues.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 23, 2026
Researchers have made significant breakthroughs in prostate cancer treatment with new imaging techniques and targeted therapies, including a PSMA-targeting antibody and a CD44v6-targeting radiotherapy. These advancements aim to improve patient outcomes by tailoring diagnosis and treatment to individual needs.
PET biomarker outperforms established risk score in predicting survival for large B-cell lymphoma patients
A new PET biomarker outperforms established risk scores in predicting survival for large B-cell lymphoma patients. Metabolic tumor volume, derived from PET imaging, was found to be an important predictor of progression-free survival.
SNMMI annual meeting to take place May 30-June 2, 2026
The SNMMI 2026 Annual Meeting will showcase the latest scientific developments driving advances in nuclear medicine, including earlier diagnosis, personalized treatment, and improved disease management for various conditions. The meeting will feature over 150 scientific sessions, satellite symposia, and a cutting-edge exhibit hall.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 10, 2026
Researchers developed a new chelator to improve cancer imaging and therapy. Additionally, analyzing brain glucose uptake in patients with non–small cell lung cancer may help predict prognosis. A targeted PET imaging agent is also being developed to detect liver cancer more effectively.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: April 3, 2026
Researchers have developed new PET tracers that can track synaptic density in epilepsy and monitor tau buildup in Alzheimer's disease. A novel PET tracer also maps cellular energy use across the body, enabling faster imaging approaches for studying mitochondrial function.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 27, 2026
Recent studies published in The Journal of Nuclear Medicine have made significant advancements in the field. Researchers have developed a new tracer to detect active collagen turnover following myocardial infarction and evaluated folate-based radioconjugates for ovarian cancer imaging. Additionally, targeted radiotherapy shows promise ...
Anil Parsram Bidkar, PhD, receives SNMMI-PCF Young Investigator's Award
Bidkar aims to develop a novel CD46-targeted radiotheranostic platform to treat metastatic castration-resistant prostate cancer. His proposal focuses on overcoming tumor heterogeneity and improving treatment outcomes.
Kiran Solingapuram Sai, PhD, receives SNMMI Mars Shot Research Fund Award
Kiran Solingapuram Sai's research aims to detect microtubule dysfunction early in Alzheimer's disease using a first-in-class PET radiotracer. The study will establish a reproducible imaging framework for this target.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 20, 2026
The study investigated the link between heart attack-induced inflammation and cognitive decline, as well as the potential of PET-based metabolic tumor volume to predict CAR T-cell therapy outcomes. Additionally, researchers combined advanced imaging with genetic profiling to explore hidden metabolic patterns in recurrent brain cancer.
Bringing diabetes treatment into focus
Researchers at Kyoto University developed a PET tracer to quantify beta cell mass in type 1 diabetes patients, revealing lower uptake in those with the disease. This measurement was inversely related to hemoglobin A1c and total daily insulin dose, suggesting its potential as a noninvasive readout of residual beta cell mass.
Scan that makes prostate cancer cells glow could cut need for biopsies
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
USC study reveals differences in early Alzheimer’s brain markers across diverse populations
Researchers at USC identified differences in early Alzheimer's disease-related brain changes across racial and ethnic groups, with Black and Hispanic participants showing higher levels of tau in key memory-related regions. The study highlights the need for more inclusive approaches to studying and diagnosing Alzheimer's disease.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: March 6, 2026
Researchers have developed new imaging techniques to detect hidden infections, inflammatory diseases, and cancers, while also evaluating the effectiveness of AI-powered tumor measurement and targeted radiotherapy for advanced solid tumors.
New PET imaging study reveals how ketamine relieves treatment-resistant depression
A new PET imaging study reveals that ketamine relieves treatment-resistant depression by altering AMPAR in brain regions, providing potential biomarker for personalized treatment. The study found that ketamine increased AMPAR density in several cortical regions and decreased it in reward-related areas, strongly correlating with reducti...
The Journal of Nuclear Medicine ahead-of-print tip sheet: February 27, 2026
Researchers have developed a new PSMA-targeted PET tracer that shows promise in early human studies, providing strong tumor uptake and favorable radiation dosimetry. Additionally, advanced dynamic PET imaging has been used to track heart amyloid buildup more precisely, detecting significant reductions after six months of tafamidis ther...
Targeted PET/CT predicts early treatment response in rheumatoid arthritis patients
A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients as little as four weeks after treatment initiation. The imaging technique uses macrophages, a type of white blood cell, as a biomarker for disease activity, potentially allowing non-responders to pursue more effective therapies.
Quantitative FDG PET and MRI framework detects emerging form of dementia, "LATE"
A novel quantitative imaging approach using PET and MRI can identify limbic-predominant age-related TDP-43 encephalopathy (LATE), a distinct neurodegenerative disorder resembling Alzheimer's disease. This framework may guide targeted diagnostic work-up and personalized care for dementia patients.
The Journal of Nuclear Medicine ahead-of-print tip sheet: February 20, 2026
Researchers have made significant advancements in nuclear medicine by developing a new reporting framework for PET/CT scans, using targeted radiation therapy to treat sarcoma, and investigating how genetic mutations affect prostate cancer treatment outcomes. These studies aim to improve diagnosis and treatment for various cancers.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 13, 2026
Researchers are testing new targeted radiation approaches for early colorectal cancer, HER2-positive breast cancer, and advanced prostate cancer. Imaging tools track treatment movement and help evaluate dosing and safety.
Ken Herrmann to be next Editor-in-Chief of The Journal of Nuclear Medicine
Ken Herrmann will lead the journal for five years, focusing on global engagement and impact. He succeeds Johannes Czernin, who guided JNM through significant growth and expansion.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 6, 2026
Researchers used advanced PET imaging techniques to study the effects of traumatic spinal cord injuries on nerve cells. Additionally, whole-body PET scans were used to map brain-body immune cross-talk during immune responses.
How experiences in the womb affect alcohol drinking in adulthood
A study found that prenatal alcohol exposure changed aspects of the dopamine system in rhesus monkeys, influencing how quickly they drank alcohol in adulthood. The researchers also discovered individualized neuroadaptive responses to drinking, which may promote the transition to alcohol use disorder.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: February 2, 2026
Researchers have developed new CXCR4-targeting radiolabeled peptides for cancer imaging and therapy, producing clear tumor images and extending survival in preclinical testing studies. Additionally, PET scans are being used to predict prostate cancer outcomes, identify primary aldosteronism, and guide treatment decisions.
AI machine learning can optimize patient risk assessments
A new AI-driven model predicts patient risk of suffering a major adverse cardiac event (MACE) with higher accuracy than traditional predictive models. This improvement in prognostic risk assessment could help personalize individual care plans and maintain quality of life for patients.
Novel combined PET imaging approach personalizes treatment for head and neck cancer
Researchers developed a novel combined PET imaging approach to personalize radiotherapy for head and neck cancers, creating biologic maps that show tumor characteristics. This strategy led to greater than 90% predicted tumor control probability, outperforming previous literature.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 23, 2026
This study introduces a new FAP-targeting peptide that shows strong tumor uptake and effective tumor growth inhibition when paired with lutetium-177. Additionally, researchers have identified distinct metabolic and structural brain patterns that differentiate probable LATE, Alzheimer disease, and their frequent overlap.
The Journal of Nuclear Medicine ahead-of-print tip sheet: January 16, 2026
Recent studies published in The Journal of Nuclear Medicine explore the use of interim PET scans to predict treatment response and survival in patients with large B-cell lymphoma. Additionally, a phase 2 trial evaluates the safety and effectiveness of a radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) in advanced...
Novel theranostic model shows curative potential for gastric and pancreatic tumors
A newly developed radiopharmaceutical pair can precisely detect and effectively treat gastric and pancreatic tumors, completely eradicating tumors in preclinical models. Claudin-18.2-based theranostics could meaningfully change patient care by enabling non-invasive tumor identification and targeted radiation therapy.
The Journal of Nuclear Medicine ahead-of-print tip sheet: Jan. 9, 2026
Researchers developed new imaging approaches using specialized amino acid PET tracers to visualize aggressive breast, lung, and glioma cancers. The studies showed promising results, highlighting the potential of these tools for future cancer imaging and guiding targeted therapies.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: January 2, 2026
Researchers have developed new PET imaging tracers to detect and treat colorectal, thyroid, and lymphoma cancers. The tracers enable targeted radiation delivery, personalized dosing, and improved detection of inflammation in large blood vessels and liver lesions.
New PET imaging breakthrough expands possibilities
Researchers at Virginia Tech have developed a new method for attaching fluorine-18 to trifluoromethyl groups, enabling the tagging of previously inaccessible targets in PET scans. This breakthrough expands the range of molecules that can be imaged, potentially leading to earlier diagnoses and more targeted treatments for diseases.
The Journal of Nuclear Medicine ahead-of-print tip sheet: December 12, 2025
Recent studies explored novel biomarkers for kidney cancer spread detection, heart scans for ATTR amyloidosis diagnosis, and radiation therapy delivery for neuroendocrine tumors. Additionally, researchers developed a new PET tracer to track heart-healing cells after a heart attack.
An ECOG-ACRIN imaging study solves a long-standing gap in metastatic breast cancer research and care: accurately measuring treatment response in patients with bone metastases
A prospective multicenter trial validated an improved method for predicting treatment benefits in hormone receptor-positive metastatic breast cancer with bone metastases. Metabolic change assessed by FDG-PET/CT accurately predicted progression-free survival as early as 12 weeks after treatment initiation.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: December 5, 2025
Recent studies explore new PET/CT imaging methods for prostate cancer staging and detection. Researchers assess improved performance of these advanced scans in detecting lymph node or bone spread, as well as their impact on treatment plans. Additionally, researchers examine the effectiveness of peptide receptor radionuclide therapy (PR...
Blood test shows obesity speeds Alzheimer’s development
A new study published at the Radiological Society of North America annual meeting found that individuals with obesity have a 95% faster increase in Alzheimer's disease biomarkers compared to non-obese individuals. Blood tests were more sensitive than PET scans in capturing the impact of obesity on Alzheimer's pathology.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 21, 2025
Several studies examine imaging tools for detecting prostate cancer, testing new PET tracers for spotting aggressive tumors. Researchers also explored a new scan to detect gastrointestinal stromal tumors and improved imaging agents for pancreatic cancer diagnosis.
Could this precision medicine approach help you delay dementia?
A new study by UC San Francisco combines genetic risk with cardiovascular disease risk factors to predict who is more likely to develop dementia. The expanded view may help those worried about dementia, as lifestyle changes and improved control of illnesses can reduce brain damage and potentially delay or prevent symptoms.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 14, 2025
Researchers have made significant advancements in detecting and treating prostate cancer and ALS using innovative imaging techniques. A new PET tracer has been developed to track Huntington disease protein aggregates, offering a potential noninvasive monitoring tool. Additionally, studies have compared two types of PET scans for spotti...
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: November 7, 2025
Researchers developed a detailed kidney model to study radiation distribution, highlighting uneven exposure across different nephron types. Tumor volume changes and PSMA PET imaging also showed promise for predicting outcomes in prostate cancer patients. New targeted therapies and imaging strategies aim to improve diagnosis and treatment.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 24, 2025
Researchers have developed a new PET imaging agent that can distinguish true tumor response from inflammation during immune checkpoint inhibitor therapy. This breakthrough has the potential to improve early treatment assessment and patient outcomes.
PET imaging of inflammation predicts recovery, guides therapy after heart attack
A new approach to PET imaging can identify patients at risk of poor functional recovery after a heart attack by visualizing CXCR4, a cellular protein involved in inflammation. This technique enables timely implementation of treatments to mitigate inflammation and prevent heart failure progression.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 17, 2025
Recent studies published in The Journal of Nuclear Medicine explore the use of artificial intelligence to improve PSMA PET/CT scan interpretation, as well as its impact on treatment decisions for patients with recurrent prostate cancer. Brain metabolic changes and fibroblast activation protein (FAP) PET imaging also reveal new insights...
New AI tool makes medical imaging process 90% more efficient
MetaSeg achieves the same segmentation performance as U-Nets but requires 90% fewer parameters, making medical image segmentation more cost-effective. The new approach leverages implicit neural representations to quickly adjust to new images and decode accurate labels.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 10, 2025
Studies have found that men with advanced prostate cancer can benefit from continuing PSMA therapy despite early PSA rise, while a new PET/CT scan may improve surgery decisions in pancreatic cancer. Molecular imaging advancements also hold promise for distinguishing aggressive kidney cancers and guiding treatment decisions.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: October 6, 2025
Recent studies published in The Journal of Nuclear Medicine have made significant breakthroughs in prostate cancer treatment, with multiple therapies showing promise. Researchers have also discovered ways to reduce radiation exposure in PET scans and tracked the effects of alpha therapy on patients.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 26, 2025
Researchers have developed promising therapies for advanced prostate cancer, improved brain imaging capabilities, and enhanced liver cancer detection. A new alpha therapy shows promise in treating thyroid cancer, while AI-assisted tracking systems enhance prognosis prediction in prostate cancer imaging.
$10 million for Neuro-led project seeking new Alzheimer’s biomarkers
A $10-million grant from the Weston Family Foundation will fund a project at McGill University to discover new Alzheimer's biomarkers. The ultra-high-sensitivity whole body PET/CT scanner, Panorama GS, will aid in understanding disease progression and developing personalized therapies.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
A new PET tracer, 64Cu-NOTA-EV-F(ab′2), has been developed for same-day imaging of triple-negative breast and urothelial bladder cancers. The tracer exhibits rapid tumor accumulation and high specificity in nectin-4 positive tumors, enabling accurate non-invasive visualization of this protein.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 19, 2025
Faster PET scans show promise for detecting liver inflammation and metabolic dysfunction-associated steatohepatitis. An AI tool combines multiple PET scans to integrate data from different tracers, improving disease insights. New imaging techniques enhance breast cancer surgery and predict recovery after heart attack.
Novel PET tracer detects synaptic changes in spinal cord and brain after spinal cord injury
Researchers developed a new PET tracer that effectively identifies synapse loss in the spinal cord and brain after spinal cord injury. The study found reduced uptake of the tracer at the injury site and in the amygdala and cerebellum, suggesting potential for diagnosing and monitoring spinal cord injuries.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: September 12, 2025
New PET imaging agents show promise for detecting thyroid and neuroendocrine tumors, as well as reversing fibrosis in the heart. Researchers also explored tau PET scans for Alzheimer's detection and SSTR PET/CT for meningioma diagnosis. These advancements hold potential for improving cancer treatment and patient outcomes.
AI can evaluate social situations similar to humans
A new study from the University of Turku found that AI systems can accurately evaluate social features from images and videos, comparable to human evaluations. The researchers compared AI's evaluations with those made by over 2,000 humans, showing that AI's results were consistently accurate.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 29, 2025
Researchers have developed new PET tracers to monitor immune responses and inflammation beyond the lungs throughout the course of SARS-CoV-2 infection. These breakthroughs offer a new way to visualize changes in lymph nodes, spleen, and bone marrow, supporting faster and more comprehensive imaging.
Total-body PET imaging takes a look at long COVID
Researchers are using total-body PET imaging to investigate the relationship between long COVID symptoms and activated immune T cells, as well as blood vessel damage. The goal is to gain a better understanding of how these processes are related and how they contribute to long COVID symptoms.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 22, 2025
Researchers have published three studies using new imaging approaches to detect and treat various types of cancer. These advancements include positronium lifetime tomography for sharper scans, targeted radiotherapy for sarcoma patients, and biomarkers for endometrial cancer diagnosis.
The Journal of Nuclear Medicine Ahead-of-Print Tip Sheet: August 15, 2025
Recent studies have shown promising results for triple-targeted cancer therapy, new PET imaging tracers tracking immune activation, and reducing PET scan doses while maintaining diagnostic accuracy. These advancements hold promise for improving cancer treatment outcomes and precision medicine.